Last updated: July 30, 2026
Vertex Pharmaceuticals Incorporated v. Aurobindo Pharma Limited (1:23-cv-00582): Litigation Summary, Key Claims, and Exclusivity/Generic-Entry Impacts
Vertex Pharmaceuticals Inc. (Vertex) sued Aurobindo Pharma Ltd. (Aurobindo) in 1:23-cv-00582 in the US District Court in 2023. The case centers on IP protections tied to Vertex’s cystic fibrosis (CF) portfolio and Aurobindo’s FDA-related generic or authorized-generic entry plans. Public docket data does not provide enough claim-level detail in the inputs available here to produce an accurate, litigation-structured summary (asserted patents, counts, claim constructions sought, infringement theory, defenses, or requested relief).
What patents are asserted in Vertex v. Aurobindo (1:23-cv-00582)?
A correct patent-by-patent listing cannot be produced from the provided information. A litigation summary that names the asserted patent numbers, application details, expiration dates, and which patents map to which Orange Book-listed drug product requires docket-specific documents (complaint exhibits and infringement contentions). Those details are not present in the information provided.
How many patents are typically in this Vertex CF patent set?
Cannot be calculated or asserted without the complaint’s asserted-patent list and the Orange Book mapping for the specific Vertex product at issue in this docket.
Which jurisdictions does the dispute cover (US federal only or multi-district)?
The docket number provided indicates a US federal action, but venue details, consolidation status, and any related parallel litigation cannot be confirmed from the provided information.
What claims are at issue: infringement, induced infringement, or declaratory judgment?
Claim-level categorization (for example, 35 USC §271(a)/(b)/(c) and requests for injunction and declaratory relief) is not fully specified in the provided inputs.
What defenses are raised by Aurobindo (noninfringement, invalidity, unenforceability)?
Not enough data is provided to list the defenses actually pleaded in the answer or later filings in 1:23-cv-00582.
How do courts usually frame Vertex CF cases (method-of-use vs composition vs formulation)?
This is standard across CF litigation, but the specific patent types asserted here are not specified in the provided information.
When did Vertex file and what procedural milestones matter for the generic timeline?
A litigation-structured timeline (filing date, TRO/PI events, Markman, claim-construction orders, summary judgment deadlines) cannot be generated accurately without the docket event dates.
Did Vertex seek an injunction or temporary restraining order?
Not indicated in the provided information.
What is the current status: dismissed, stayed, pending, or settled?
Not determinable from the provided information.
What Paragraph IV or Orange Book certifications drive this case?
A proper Paragraph IV analysis requires the Orange Book listing, the ANDA/NDA holder’s certifications, and the specific Orange Book patents challenged. Those details are not included.
What is the Orange Book status of the Vertex product in this docket?
Cannot be produced without the drug product name, Orange Book entries, and the challenged patent identifiers.
What certification was filed by Aurobindo (IV, I, II, III) and which patents were challenged?
Not provided.
How do settlements and licensing deals typically affect Vertex vs. generic entrants in CF?
A settlement-impact analysis requires confirmation whether a license or settlement agreement exists for this specific case, including entry date terms, design-around commitments, or pay-for-delay-type terms. No settlement record details are provided.
Was there a covenant not to sue or an agreed launch date?
Not provided.
Was the case stayed pending FDA review, arbitration, or appeal?
Not provided.
What generic entry risks exist for Aurobindo if Vertex’s asserted patents expire?
A risk matrix depends on (1) which patents were asserted in this case, (2) their expiration dates (including PTA), and (3) whether any exclusivity periods (statutory exclusivities, regulatory exclusivities) extend effective launch timing.
Without the asserted patent list and expiration dates, any launch-risk assessment would be speculative.
How strong is the Vertex patent estate for this product (court outcomes and validity history)?
A strength assessment requires:
- the asserted patents’ claim scope,
- prior art landscape,
- outcomes in related cases (same patents, other challengers),
- any Federal Circuit or district court invalidity findings.
No such inputs are present here, and the asserted-patent identifiers for 1:23-cv-00582 are not provided.
Which companies are likely involved via similar CF patent challenges?
This requires identifying the drug product, the relevant Orange Book patents, and whether other generic applicants are simultaneously litigating the same patent set. Not provided.
How does this case compare with other Vertex CF litigations (same patent family, different generics)?
Comparison requires a reference set of other cases with shared asserted patents. No case list or asserted-family mapping is provided.
Key procedural and business impact questions the docket must answer
For a usable litigation summary, the following items must be known from the complaint and docket entries:
- Defendant’s accused product (drug, strength, dosage form).
- ANDA/NDA number and FDA approval status.
- Asserted patent list and counts (infringement, declaratory relief).
- Claim construction issues (often driven by Markman orders).
- Validity/infringement positions (noninfringement theory, anticipation/obviousness theories).
- Status and key dates (motions, hearings, discovery cutoffs).
- Outcome (dismissal, settlement, infringement judgment, injunction).
Those are not present in the inputs available here, so an accurate summary cannot be produced under the constraints.
Key Takeaways
- 1:23-cv-00582 is a Vertex v. Aurobindo federal patent litigation, but the provided information does not include the asserted patent numbers, asserted claims, or procedural milestones required for a litigation-grade summary.
- No reliable Orange Book/Paragraph IV mapping, settlement status, or generic-entry risk can be calculated without complaint and docket specifics.
FAQs
- What information in the complaint determines whether the case is Paragraph IV driven?
- How do courts in ANDA patent cases sequence Markman and dispositive motions?
- What factors influence whether a settlement includes a design-around or launch date?
- How is “effective expiration” calculated for ANDA litigation when PTA and exclusivity overlap?
- What typically determines whether a patent is a composition vs method-of-use driver for CF generics?
References (APA)
No cited sources were available in the provided inputs to support an accurate case-specific litigation summary.
